Asthma

Severe Asthma

Severe asthma remains uncontrolled despite high-dose treatment — requires specialist evaluation for phenotype and biologic therapy.

Overview

Severe asthma is defined as asthma that remains uncontrolled despite high-dose inhaled corticosteroids plus a second controller — affecting about 5–10% of asthma patients but accounting for disproportionate healthcare costs and mortality.

The term covers difficult-to-treat asthma (which may improve with correct diagnosis, adherence or comorbidity management) and true severe asthma requiring advanced therapies. Specialist evaluation identifies the phenotype (eosinophilic, allergic, neutrophilic) and determines eligibility for biologic therapies that have transformed severe asthma management.

Symptoms

  • Persistent symptoms despite high-dose medication
  • Frequent exacerbations requiring oral steroids or hospitalization
  • Night waking from asthma
  • Limited daily activities
  • Heavy reliance on reliever inhaler
  • Oral corticosteroid dependence
  • Reduced lung function on spirometry

Potential Triggers

  • All the usual asthma triggers, often harder to control
  • Comorbidities: rhinosinusitis with polyps, obesity, reflux
  • Medication factors: adherence, technique, drug interactions
  • Environmental exposures that are difficult to eliminate
  • Psychological factors: anxiety, depression

Diagnostic Assessment

  • Confirmation of severe asthma phenotype
  • Assessment of inhaler technique and adherence
  • Exclusion of mimics: vocal cord dysfunction, cardiac asthma, bronchiectasis
  • Biomarker testing: blood eosinophils, FeNO, IgE
  • Comorbidity screening: rhinosinusitis, reflux, obesity, sleep apnea
  • Evaluation for biologic therapy eligibility

Treatment Approaches

  • Optimization of inhaler technique and adherence first
  • High-dose ICS/LABA combination
  • Add-on LAMA (tiotropium)
  • Oral corticosteroids — lowest effective dose, shortest duration
  • Biologics: anti-IgE (omalizumab), anti-IL5 (mepolizumab, benralizumab), anti-IL4Rα (dupilumab), anti-TSLP (tezepelumab)
  • Treatment of comorbidities
  • Bronchial thermoplasty in selected cases

Ongoing Management

  • Specialist-led care at a severe asthma center
  • Structured follow-up with biomarker monitoring
  • Written asthma action plan
  • Minimizing oral corticosteroid exposure
  • Vaccination and infection prevention
  • Psychological support for chronic disease burden
  • Patient education on recognizing deterioration

Frequently Asked Questions

Is severe asthma the same as difficult-to-treat asthma?

Not exactly — difficult-to-treat asthma may improve with correct diagnosis, adherence or comorbidity management. True severe asthma remains uncontrolled despite optimized therapy and requires advanced treatments like biologics.

What are biologics for asthma?

Targeted monoclonal antibodies that block specific inflammatory pathways (IgE, IL-5, IL-4/IL-13, TSLP). They have transformed severe asthma, dramatically reducing exacerbations for eligible patients.

Can I ever reduce my asthma medications?

Yes — with good control, step-down therapy is possible. Specialist-guided de-escalation maintains control while reducing medication burden, especially important for oral steroids.

Related Pages

Ready to get answers?

Book a specialist consultation to discuss your symptoms and treatment options.

Medical disclaimer: This page is for educational purposes and does not constitute medical advice. Individual diagnosis and treatment require consultation with a qualified healthcare professional. If you are experiencing a medical emergency, seek immediate care.